Ana PDF
Ana PDF
indirect immunofluorescence
EUROIMMUN AG · Seekamp 31 · 23560 Lübeck (Germany) · Tel +49 451/ 58 55-0 · Fax 58 55-591 · [email protected] · www.euroimmun.com
Table of contents
Autoantibodies against cell nuclei (ANA) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
Autoantibodies negative (AC-0) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
Autoantibodies against cell nuclei, homogeneous (AC-1) . . . . . . . . . . . . . . . . 11
Autoantibodies against dsDNA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
Autoantibodies against cell nuclei, DFS pattern (AC-2) . . . . . . . . . . . . . . . . . . 13
Autoantibodies against centromeres (AC-3) . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
Autoantibodies against nucleoplasm, fine speckled (AC-4). . . . . . . . . . . . . . . 15
Autoantibodies against Ku (AC-4) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
Autoantibodies against Mi-2 (AC-4) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
Autoantibodies against TIF1-gamma (AC-4) . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
Autoantibodies against nucleoplasm, coarse speckled (AC-5) . . . . . . . . . . . . 19
Autoantibodies against nuclear dots (AC-6) . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
Autoantibodies against few nuclear dots (AC-7) . . . . . . . . . . . . . . . . . . . . . . . 21
Autoantibodies against PM-Scl (AC-8). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
Autoantibodies against U3-nRNP / fibrillarin (AC-9) . . . . . . . . . . . . . . . . . . . . . 23
Autoantibodies against RNA polymerase I (AC-10) . . . . . . . . . . . . . . . . . . . . . 24
Autoantibodies against NOR-90 (AC-10) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
Autoantibodies against nucl. membrane (AC-11 / AC-12) . . . . . . . . . . . . . . . . . 26
Autoantibodies against PCNA (AC-13). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
Autoantibodies against CENP-F (Cyclin II – Mitosin) (AC-14) . . . . . . . . . . . . . 28
Autoantibodies against F-actin (AC-15) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
Autoantibodies against tropomyosin (AC-16) . . . . . . . . . . . . . . . . . . . . . . . . . . 30
Autoantibodies against vimentin (AC-16) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
Autoantibodies against vinculin (AC-17) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
Autoantibodies against lysosomes (AC-18) . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
Autoantibodies against PL-7 and PL-12 (AC-19) . . . . . . . . . . . . . . . . . . . . . . . . 34
Autoantibodies against ribosomal P proteins (AC-19) . . . . . . . . . . . . . . . . . . . 35
Autoantibodies against SRP (AC-19) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
Autoantibodies against Jo-1 (AC-20) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
Autoantibodies against mitochondria (AC-21) . . . . . . . . . . . . . . . . . . . . . . . . . 38
Autoantibodies against Golgi apparatus (AC-22) . . . . . . . . . . . . . . . . . . . . . . . 39
Cytoplasmic rods and rings (AC-23) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
Autoantibodies against centrosomes (AC-24). . . . . . . . . . . . . . . . . . . . . . . . . . 41
Autoantibodies against spindle fibres (AC-25) . . . . . . . . . . . . . . . . . . . . . . . . . 42
Autoantikörper gegen NuMA (AC-26) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
Autoantibodies against midbody (AC-27) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
Autoantibodies against MCA (AC-28) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
Autoantibodies against Topoisomerase I (Scl-70) (AC-29) . . . . . . . . . . . . . . . 46
Dilution scheme for immunofluorescence . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
EUROPattern: Automated evaluation of IIFT . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
Autoantibodies against cell nuclei (ANA)
Definition
Analytics
Due to its high sensitivity and specificity, the indirect immunofluorescence test
(IIFT) using human epithelial cells (HEp-2) and primate liver is the gold standard
for the detection of anti-nuclear autoantibodies (ANA). The signal intensities of
a positive and a negative sample differ significantly and microscopic evaluation
allows an exact determination of how the indicator dye (usually fluorescein) is
spread in the tissue or cells. Each bound autoantibody causes a typical fluores-
cence pattern, depending on the location of the corresponding autoantigen.
If the analysis result is positive, test substrates with defined single antigens
(ELISA, western blot, line blot) are used for further differentiation. Using mo-
nospecific test methods alone is not sufficient for the determination of anti-
nuclear autoantibodies since not all relevant antigens are available in their puri-
fied form. For verification of analysis results, monospecific tests should always
be accompanied by IIFT.
3
Evaluation
4
and Sm are also considered to be pathognomonic for SLE. Antibodies against
other polynucleotides, ribonucleotides, histones and further nuclear antigens
can also be detected in this disease. In drug-induced lupus erythematosus
with manifestations such as arthralgia, arthritis, exanthema, serositis, myalgia,
heptomegalia and splenomegalia, antibodies against histones are constantly
observed. This reversible form of SLE can be induced by antibiotics (e.g. peni-
cillin, streptomycin, tetracyclines), chemotherapeutic agents (e.g. INH, sul-
fonamides), anticonvulsants (e.g. phenytoin, hydantoines), antiarrythmics
(e.g. procainamide, practolol), antihypertensives (e.g. reserpine, hydralazine),
psychotropics (e.g. chlorpromazine), anti-thyroid drugs (e.g. thiouracil deriva-
tives), anti-rheumatoid basis therapeutics (e.g. gold, D penicillamine) and other
drugs such as contraceptives and allopurinol.
High autoantibody titers against U1-nRNP are characteristic for mixed connec-
tive tissue disease. The antibody titer correlates with the activity of the disease.
5
Autoantibodies in mixed connective tissue disease (MCTD, Sharp syndr.)
Antigen Prevalence (%)
U1-nRNP 95 – 100
Single-stranded DNA 20 – 50
Rheumatoid arthritis
6
Autoantibodies in progressive systemic sclerosis (diffuse form)
Antigen Prevalence (%)
Topoisomerase I (Scl-70) 25 – 75
RNA polymerase I 4
Ku, incl. overlap syndrome with PM/DM 25 – 50
7-2-RNP (To) rare
NOR-90 (nucleolar organiser region) rare
Polymyositis / dermatomyositis
Sjögren‘s syndrome
In (primary) Sjögren‘s syndrome, antibodies against SS-A and SS-B are pre-
sent, mainly in combination with one another. In addition, autoantibodies
against the salivary secretory ducts are found in 40 to 60 % of cases.
8
Anti-nuclear autoantibodies: The most important associated diseases
Antigen Disease Prevalence (%)
Drug-induced SLE 95
Histones SLE 50 – 80
RA 15 – 50
MCTD (Sharp syndrome) 95 – 100
U1-nRNP SLE 15 – 40
RA 3
Sm SLE 5 – 40
Sjögren‘s syndrome 40 – 95
SS-A (Ro) SLE 20 – 60
Neonatal lupus syndrome 100
Sjögren‘s syndrome 40 – 95
SS-B (La)
SLE 10 – 20
Fibrillarin PSS, diffuse 5 – 10
RNA polymerase I PSS, diffuse 4
RNA helicase A SLE 6
Poly- / dermatomyositis / overlap syndr. 24 – 55
PM-Scl (PM-1)
PSS, diffuse 13
Centromeres PSS, limited 80 – 95
Topoisomerase I PSS, diffuse 25 – 75
PCNA-like SLE 3
SLE 10
Ku
Poly- / dermatomyositis, PSS 25 – 50
Mi-1, Mi-2 Dermatomyositis 5 – 30
9
Autoantibodies negative (AC-0)
HEp-2 cells
10
Autoantibodies against cell nuclei, homogeneous (AC-1)
HEp-2 cells show a homogeneous fluorescence of the cell nuclei. The con-
densed chromosomes of mitotic cells are positive. The area surrounding the
chromosomes is dark.
11
Autoantibodies against dsDNA
AAb against dsDNA pos. AAb against dsDNA neg. AAb against dsDNA neg.
(kinetoplast) (cell nucleus) (basal body)
The standard substrate for the immunofluorescence test is the haemoflagel-
late Crithidia luciliae. It possesses a dsDNA-containing giant mitochondrion
(kinetoplast) which, apart from dsDNA, essentially displays no antigens which
occur also in the cell nucleus. Antibodies which react with the kinetoplast are
therefore directed exclusively against dsDNA. With C. luciliae they produce a
homogenous, partly edge-accentuated fluorescence of the kinetoplast. Any
reaction in the cell nucleus is not evaluated; fluorescence in the basal body
of the flagellum is without significance. Antibodies to ssDNA cannot stain the
kinetoplast.
12
Autoantibodies against cell nuclei, DFS pattern (AC-2)
HEp-2 cells
On the substrate HEp-2 cells autoantibodies against the DFS70 antigen (and
possibly other antigens) depict a uniformly distributed dense fine speckled
fluorescence with granular staining of the condensed chromosomes.
13
Autoantibodies against centromeres (AC-3)
On tissue sections of primate liver 10 to 20 granules, which are spread over the
cell nucleus, can be seen. The fluorescence of these granules is significantly
weaker than the HEp-2 cell staining and is therefore easy to miss. Mitotic cells
are only rarely detected on liver substrate.
14
Autoantibodies against nucleoplasm, fine speckled (AC-4)
HEp-2 cells show a fine speckled fluorescence of the cell nuclei in the inter-
phase. The nucleoli are also reactive, but they are slightly silhouetted against
the nucleoplasm. In some samples they do not react at all. Mitotic cells show a
speckled fluorescence, with the chromosomes excluded.
15
Autoantibodies against Ku (AC-4)
16
Autoantibodies against Mi-2 (AC-4)
With primate liver, autoantibodies against Mi-2 depict a fine speckled fluores-
cence of the hepatocyte nuclei.
Clinical association: Antibodies against Mi-2 are highly specific markers for der-
matomyositis with nail fold hypertrophy. They are found in 5 – 30 % of patients
with dermatomyositis and in 8 – 12 % of patients with idiopathic myositis.
17
Autoantibodies against TIF1-gamma (AC-4)
Antibodies against TIF1-gamma react with the transfected cells of the test sub-
strate. They produce a smooth to fine speckled fluorescence in the cytoplasm.
The cell nuclei are generally only slightly stained.
18
Autoantibodies against nucleoplasm, coarse speckled (AC-5)
Tissue sections of primate liver also show a speckled fluorescence. The nucle-
oli do not react. The antibodies react with primate liver to the same extent as
with HEp-2 cells.
19
Autoantibodies against nuclear dots (AC-6)
Antibodies against nuclear dots react with primate liver to the same extent as
with HEp-2 cells. If both substrates are used in parallel, these antibodies can
even be identified if antibodies against centromeres are present at the same
time. This can occasionally be observed in cases of primary biliary cholangitis.
20
Autoantibodies against few nuclear dots (AC-7)
In the immunofluorescence on HEp-2 cells, the pattern few nuclear dots merely
shows 1 – 6 dots per cell nucleus – frequently near the nucleoli. In the late S / G2
phase of the cell cycle, the cells show relatively many dots (4 – 6). The meta-
phase chromatin is usually negative. These nucleolar dots are denominated
Cajal bodies (formerly: coiled bodies).
On the primate liver tissue section the dots manifest slightly augmented in
comparison with the HEp-2 cells. The liver may, however, also show a negative
reaction.
21
Autoantibodies against PM-Scl (AC-8)
22
Autoantibodies against U3-nRNP / fibrillarin (AC-9)
23
Autoantibodies against RNA polymerase I (AC-10)
24
Autoantibodies against NOR-90 (AC-10)
HEp-2 cells
On HEp-2 cells in the metaphase, one to few little dots fluoresce within the con-
densed chromosome material. They correspond to the nucleolus organisator
(NOR). The cytoplasm of mitotic cells may be weakly positive. Interphase cells
show a granular fluorescence of the nuceloli.
25
Autoantibodies against nucl. membrane (AC-11 / AC-12)
Known target antigens: gp210, lamin A, lamin B and C, and lamin B receptor.
26
Autoantibodies against PCNA (AC-13)
Clinical association: PCNA antibodies are specific for SLE. The prevalence,
however, is only 3 %.
27
Autoantibodies against CENP-F (Cyclin II – Mitosin) (AC-14)
HEp-2 cells
28
Autoantibodies against F-actin (AC-15)
On tissue sections of primate liver there is a strong reaction of the bile canali-
culi.
29
Autoantibodies against tropomyosin (AC-16)
30
Autoantibodies against vimentin (AC-16)
Antibodies against vimentin cause staining of a fine net of fibres in the cyto-
plasm of HEp-2 cells. The net is particularly dense near the cell nuclei. In mitotic
cells numerous round fluorescing droplets can be seen outside the dark chro-
mosomes. These are probably condensed vimentin.
31
Autoantibodies against vinculin (AC-17)
The primate liver shows a fluorescence of the basal boundary surface of endo-
thelium and stroma in the sinusoids.
Clinical association: Autoantibodies agianst vinculin are very rare and are asso-
ciated with Myasthenia gravis, ulcerative colitis and Crohn‘s disease.
32
Autoantibodies against lysosomes (AC-18)
33
Autoantibodies against PL-7 and PL-12 (AC-19)
Clinical association: Antibodies against PL-7 and PL-12 occur in myositis with
a prevalence of up to 4 %.
34
Autoantibodies against ribosomal P proteins (AC-19)
35
Autoantibodies against SRP (AC-19)
36
Autoantibodies against Jo-1 (AC-20)
On frozen tissue sections of primate liver the cytoplasm is only slightly stained.
The fluorescence cannot be used for diagnostics.
37
Autoantibodies against mitochondria (AC-21)
HEp-2-cells contain the antigens M2, M3, M5 and M9; here the antibodies pro-
duce a coarse speckled fluorescence of the cytoplasm which does not include
the nucleus (previously, the likewise PBC-relevant nuclear dots also reacting
were wrongly suspected of being stray mitochondria).
The primate liver shows a speckled fluorescence of the cytoplasm. The cell
nuclei are dark. The reaction of the tissue is generally weaker than that of HEp-2
cells.
38
Autoantibodies against Golgi apparatus (AC-22)
39
Cytoplasmic rods and rings (AC-23)
HEp-2 cells
Rods and rings are a cytoplasmic pattern on HEp-2 cells that has been described
only recently. These filamentous structures, which are expressed in all stages
of the cell cycle, present themselves as rings, rods or loops.
Known target antigens: It is assumed that the reaction is directed against the
autoantigen inosine monophosphate dehydrogenase 2 (IMPDH2).
Clinical association: The depicted pattern was observed mainly in patients with
hepatitis C infections, particularly after treatment with interferon-alpha or riba-
virin (prevalence 35 %).
40
Autoantibodies against centrosomes (AC-24)
On primate liver, high-titer samples produce small fluorescing dots in the cyto-
plasm of hepatocytes.
Clinical association: A high titer (> 1:1,000) indicates progressive systemic scle-
rosis or Raynaud’s syndrome, the prevalence however, only amounts to a few
percent. The pattern was also observed in infections.
41
Autoantibodies against spindle fibres (AC-25)
HEp-2 cells
Using HEp-2 cells, antibodies against the spindle fibre antigen MSA-2 (HsEG5)
can be detected. In the presence of these antibodies only the spindle fibres of
the mitotic cells, but not the cell nuclei of the interphase cells are stained.
On tissue sections of primate liver a speckled fluorescence of the cell nuclei can
be observed.
42
Autoantikörper gegen NuMA (AC-26)
43
Autoantibodies against midbody (AC-27)
HEp-2 cells
44
Autoantibodies against MCA (AC-28)
HEp-2 cells
On Hep-2 cells, the chromosomes in the pro- and methaphase show a dotted
fluorescence. Interphase nuclei do not present any staining.
45
Autoantibodies against Topoisomerase I (Scl-70) (AC-29)
HEp-2 cells show a fine granular nuclear fluorescence in interphase cells. The
nucleoli are positive, showing a homogeneous fluorescence. The cytoplasm is
dark. In mitotic cells the border area of condensed chromosomes fluoresces,
sometimes the entire chromosomal region is positive.
On rat kidney tissue sections, the cell nuclei of the tubular epithelium fluoresce.
46
Dilution scheme for immunofluorescence
For all its immunofluorescence test systems EUROMMUN recommends choos-
ing a titration of serum samples that provides the best basis for evaluation.
Previously, the accuracy was excessive due to use of quadratic dilution steps.
On the other hand, titrating by a factor of 4 results in too rough a framework.
Therefore, we recommend using a dilution scheme based on the square root of
10 to yield dilution steps of 1 : 10, 1 : 32, 1 : 100, 1 : 320, 1 : 1.000 and so on.
For every test parameter there is a suitable starting dilution. In order to sim-
plify the test procedure and evaluation of results, two antibody categories are
differentiated at EUROIMMUN: Antibodies of group I are already diagnostically
relevant at at titer of 1:10, while those of group II first at 1:100.
Serum
1:10 1:32 1:100 1:320 1:1,000 1:3,200 1:10,000
dilution
Evaluation,
+ ++ ++ +++ +++ ++++ ++++
group I
Evaluation,
+ ++ +++ ++++ ++++
group II
47
Blocking effect: In two out of every 100 high-titer sera an untypical result is
seen with the starting dilution. Some strongly positive sera even react as false
negative if they are not sufficiently diluted.
48
Titer estimation: When two dilutions made at an interval of factor 10 are used,
a titer can be determined for most positive results without further incubations
(see table). Results are obtained one day earlier than with stepwise titrations.
Fluorescence at
1:100 1:1,000 AAb titer
weak negative 1:100
strong negative 1:320
strong weak 1:1,000
strong moderate 1:3,200
strong strong 1:10,000
49
EUROPattern: Automated evaluation of IIFT
EUROPattern Microscope
For each pattern a titer is automatically calculated from the fluorescence inten-
sities of the incubated dilutions, which ensures reproducible quantification.
51
Drug.-induced lupus erythematosus
SYSTEMIC
Polymyositis / Dermatomyositis
Paraneoplastic autoimmunity
Anti-phospholipid syndrome
ASSOCIATED
Autoimmune hepatitis
Rheumatoid arthritis
Sjögren‘s syndrome
Habitual abortions
Domains of immunofluorescence
Diagnostically
essential
relevant
Mi-2
SRP
cN-1A (Mup44)
Jo-1
TIF1-gamma
MDA5, NXP2, SAE1
PL-7, PL-12, OJ, EJ, SC, KS
Nuclear dots
Sp100, Sp140, SUMO, PML
Nuclear membrane, lamin B recept.
GP210, NUP62
Cardiolipin
Beta-2 glycoprotein
Phosphatidylserine
Coagulation factor (lupus anticoag.)
Prothrombin, annexin A5
C1q
Mitochondria (AMA)
Mitochondria (AMA M2-3E / BPO)
Ribosomal P proteins
ASMA
F-actin
IgG (rheumatoid factors)
Citrullinated peptides (CCP)
Sa
Filaggrin, RA keratin
Citrullinated enolase peptide (CEP-1)
EUROIMMUN AG · Seekamp 31 · 23560 Lübeck (Germany) · Tel +49 451/ 58 55-0 · Fax 58 55-591 · [email protected] · www.euroimmun.com
FA_1510_I_UK_B09, 02 / 2019